ANIK — Anika Therapeutics, Inc.

Summary of Anika Therapeutics Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $32.6 million, a 16% increase year-over-year.
• Commercial Revenue: Grew 17% to $13.9 million, driven by international sales and product performance.
• International Revenue: Reached a record $12.6 million, up 22% year-over-year.
• OEM Channel Revenue: Grew 14% year-over-year, supported by MONOVISC demand.
• Gross Margin: Improved to 65%, up from 51% in the prior year, reflecting operational efficiencies and product mix.
• Adjusted EBITDA: $7.1 million, representing a 22% margin, the highest since 2020.
• Cash Position: Ended the quarter with $38.4 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Revenue Growth: Driven by strong performance in the international OA pain management and regenerative solutions segments, with CINGAL and MONOVISC showing significant growth.
• Operational Excellence: Continued focus on lean manufacturing practices has led to improved productivity and cost efficiency.
• Product Pipeline: Advancements in the HA-based innovation pipeline, including progress on CINGAL's bioequivalence study and ongoing FDA engagement for Hyalofast.
• Distributor Engagement: Successful international distributor meeting aimed at aligning growth priorities and enhancing execution.

3. Forward Guidance and Outlook

• Full Year 2026 Guidance:
  • OEM revenue growth revised to 0% to 5% (previously down 5% to flat).
  • Commercial channel growth expected at 12% to 18% (previously 10% to 20%).
  • Total company revenue guidance raised to 5% to 10% growth (from 1% to 9%).
  • Adjusted EBITDA margin guidance increased to 13% to 17% (from 5% to 10%).
• 2027 Revenue Forecast: New guidance practice excludes unapproved products, projecting 0% to 5% growth.

4. Bad News, Challenges, or Points of Concern

• Sequential Revenue Decline: Guidance implies a significant step down in the second half of the year due to order timing and tough comparisons with a strong Q4 in 2025.
• Pricing Pressure: Anticipated modest declines in pricing, particularly for OrthoVisc, which may offset volume growth.
• Cash Flow Lag: Current cash generation is lagging behind improvements in other metrics, attributed to higher accounts receivable from increased orders.

5. Notable Q&A Insights

• OEM Revenue Guidance: CEO Steve Griffin acknowledged that the sequential decline in OEM revenue guidance is partly due to favorable order timing in Q2 and a strong Q4 comparison from the previous year.
• Sustainability of Gross Margin: Griffin expressed confidence that mid-60s gross margins are sustainable, driven by ongoing operational improvements.
• CINGAL Study Enrollment: Enrollment in the bioequivalence study is on track for completion by year-end 2026.
• Cash Generation Strategy: Management is focused on improving cash flow, with expectations for stronger free cash flow in the second half of the year, despite current inventory investments.

This summary encapsulates Anika Therapeutics' performance and strategic direction for Q2 2026, highlighting both achievements and challenges as the company navigates its growth trajectory.